Arranta Bio Secures Funding to Serve Companies Focusing on Gene...

Arranta Bio Secures Funding to Serve Companies Focusing on Gene Therapy

Healthcare Tech Outlook | Thursday, March 19, 2020

Arranta Bio offers contract development and manufacturing services to new innovators working on pioneering therapies targeting diseases associated with the human microbiome.

FREMONT, CA: Today, around 200 companies are focused on understanding the human microbiome and its link to areas including infectious diseases and oncology to recognize therapeutic targets. The microbiome is a formation of millions of bacteria, fungi, protozoa and viruses that live inside and on the human body. Scientists have called it the second genome. The number of genes in the microorganisms making up one person's microbiome is over 200 times the number in the human genome.

Arranta Bio (Arranta), which is building a Contract Development and Manufacturing Organization (CDMO), recently announced the completion of an $82 million funding round and a decisive partnership with Thermo Fisher Scientific.

Founded in 2019, Arranta Bio was explicitly established to focus on serving businesses seeking to expand and commercialize therapies targeting the human microbiome. The company offers Live Biopharmaceutical Products (LBPs) for microbiome pioneers by bacterial fermentation, drying, isolation, and encapsulation.

Arranta's funding round was achieved with an individual institutional investor, Ampersand Capital Partners, company founders and associates, and a strategic investment from Thermo Fisher. Ampersand is a middle-market private equity firm committed to growth-oriented investments in the healthcare area. Thermo Fisher Scientific, on the other hand, is a leader in serving science, with a mission to enable its customers to make the world healthier, cleaner and safer. The enterprise helps customers accelerate life sciences research, enhance patient diagnosis, deliver medicines to market, solve complex analytical challenges and increase laboratory productivity.

Furthermore, Arranta is setting late clinical and commercial-ready capacity at a new facility in Watertown, Massachusetts, the USA that will go online mid-2020. Besides, the enterprise has built a strong leadership team to accelerate the growth of the company. By partnering with Thermo Fisher, Arranta will have access to the business's full suite of services and products and will provide materials to Thermo Fisher for use in gene therapy production.

Weekly Brief